天臣医疗（688013）7月7日主力资金净买入10.42万元

Core Viewpoint - Tianchen Medical (688013) has shown a positive stock performance with a closing price of 30.74 yuan, up 2.5% as of July 7, 2025, indicating a potential upward trend in investor sentiment [1] Financial Performance - The company reported a main revenue of 65.84 million yuan for Q1 2025, representing a year-on-year increase of 9.34% - The net profit attributable to shareholders was 13.19 million yuan, up 16.16% year-on-year - The net profit after deducting non-recurring gains and losses was 11.07 million yuan, with a slight increase of 0.5% year-on-year - The company's debt ratio stands at 13.25%, with investment income of 1.32 million yuan and financial expenses of -2.77 million yuan - The gross profit margin is reported at 58.46% [4] Market Position - Tianchen Medical's total market capitalization is 2.495 billion yuan, significantly lower than the industry average of 10.66 billion yuan, ranking 110 out of 122 in the medical device industry - The company's net assets are 572 million yuan, compared to the industry average of 3.919 billion yuan, ranking 114 out of 122 - The net profit of 13.19 million yuan ranks 77 out of 122 in the industry, while the price-to-earnings ratio (P/E) is 47.3, lower than the industry average of 57.66, ranking 58 out of 122 - The price-to-book ratio (P/B) is 4.69, higher than the industry average of 3.47, ranking 97 out of 122 - The company's net profit margin is 20.03%, significantly higher than the industry average of 10.86%, ranking 35 out of 122 - Return on equity (ROE) is reported at 2.38%, compared to the industry average of 1.01%, ranking 33 out of 122 [4] Capital Flow - On July 7, 2025, the net inflow of main funds was 104,200 yuan, accounting for 0.17% of the total transaction amount, while retail investors saw a net inflow of 1.68 million yuan, representing 2.76% of the total transaction amount - Over the past five days, the stock has experienced fluctuations in capital flow, with notable net outflows from speculative funds [1][2]